Old Web
English
Sign In
Acemap
>
authorDetail
>
Joga Gobburu
Joga Gobburu
Novartis
Medicine
Chronic myelogenous leukemia
Imatinib
imatinib mesylate
Population
4
Papers
295
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (4)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Sprycel for Chronic Myeloid Leukemia and Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia Resistant to or Intolerant of Imatinib Mesylate
2008
Clinical Cancer Research
Michael Brave
Vicki L. Goodman
Edvardas Kaminskas
Ann T. Farrell
William Timmer
Sarah Pope
Ravi Harapanhalli
Haleh Saber
David L. Morse
Julie Bullock
Angela Men
Carol Noory
Roshni Ramchandani
Leslie Kenna
Brian Booth
Joga Gobburu
Xiaoping Jiang
Rajeshwari Sridhara
Robert Justice
Richard Pazdur
Show All
Source
Cite
Save
Citations (203)
Report from the FDA Approval Summary: Imatinib Mesylate Capsules for Treatment of Adult Patients with Newly Diagnosed Philadelphia Chromosome- positive Chronic Myelogenous Leukemia in Chronic Phase
2003
John R. Johnson
Peter F. Bross
Martin H. Cohen
Mark D. Rothmann
Gang Chen
Anne Zajicek
Joga Gobburu
Atiqur Rahman
Ann Staten
Richard Pazdur
Show All
Source
Cite
Save
Citations (2)
Approval summary: Imatinib mesylate capsules for treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in chronic Phase
2003
Clinical Cancer Research
John R. Johnson
Peter F. Bross
Martin H. Cohen
Mark D. Rothmann
Gang Chen
Anne Zajicek
Joga Gobburu
Atiqur Rahman
Ann Staten
Richard Pazdur
Show All
Source
Cite
Save
Citations (86)
A population pharmacokinetic model for zoledronic acid (ZOMETA) in patients with bone metastases
2003
Clinical Pharmacology & Therapeutics
B. P. Booth
A. Rahman
A. Ibrahim
N. Scher
G. Williams
Horst Schran
Peiming Ma
Chyi‐Hung Hsu
Joga Gobburu
Show All
Source
Cite
Save
Citations (4)
1